vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and UPEXI, INC. (UPXI). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $8.1M, roughly 1.1× UPEXI, INC.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -2222.1%, a 2161.8% gap on every dollar of revenue. On growth, UPEXI, INC. posted the faster year-over-year revenue change (101.0% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-2.7M). Over the past eight quarters, UPEXI, INC.'s revenue compounded faster (24.2% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
PLX vs UPXI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $8.1M |
| Net Profit | $-5.5M | $-178.9M |
| Gross Margin | 49.4% | 83.3% |
| Operating Margin | -51.1% | -2177.9% |
| Net Margin | -60.3% | -2222.1% |
| Revenue YoY | -49.9% | 101.0% |
| Net Profit YoY | -184.8% | -13649.6% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $8.1M | ||
| Q3 25 | $17.9M | $9.2M | ||
| Q2 25 | $15.7M | $4.3M | ||
| Q1 25 | $10.1M | $3.2M | ||
| Q4 24 | $18.2M | $4.0M | ||
| Q3 24 | $18.0M | $4.4M | ||
| Q2 24 | $13.5M | $5.0M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | $-5.5M | $-178.9M | ||
| Q3 25 | $2.4M | $66.7M | ||
| Q2 25 | $164.0K | $-6.9M | ||
| Q1 25 | $-3.6M | $-3.8M | ||
| Q4 24 | $6.5M | $-1.3M | ||
| Q3 24 | $3.2M | $-1.6M | ||
| Q2 24 | $-2.2M | $-15.7M | ||
| Q1 24 | — | $-4.1M |
| Q4 25 | 49.4% | 83.3% | ||
| Q3 25 | 53.4% | 89.6% | ||
| Q2 25 | 62.5% | 79.4% | ||
| Q1 25 | 19.1% | 49.3% | ||
| Q4 24 | 78.7% | 74.3% | ||
| Q3 24 | 53.4% | 67.3% | ||
| Q2 24 | 29.8% | 31.0% | ||
| Q1 24 | — | 24.3% |
| Q4 25 | -51.1% | -2177.9% | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 7.5% | -151.7% | ||
| Q1 25 | -41.0% | -113.5% | ||
| Q4 24 | 39.6% | -26.8% | ||
| Q3 24 | 22.2% | -30.6% | ||
| Q2 24 | -18.0% | -265.2% | ||
| Q1 24 | — | -96.5% |
| Q4 25 | -60.3% | -2222.1% | ||
| Q3 25 | 13.2% | 722.4% | ||
| Q2 25 | 1.0% | -161.5% | ||
| Q1 25 | -35.8% | -121.2% | ||
| Q4 24 | 35.6% | -32.5% | ||
| Q3 24 | 18.0% | -37.3% | ||
| Q2 24 | -16.4% | -312.4% | ||
| Q1 24 | — | -78.9% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | $0.76 | ||
| Q2 25 | $0.00 | $0.83 | ||
| Q1 25 | $-0.05 | $-2.87 | ||
| Q4 24 | $0.10 | $-1.24 | ||
| Q3 24 | $0.03 | $1.55 | ||
| Q2 24 | $-0.03 | $-15.66 | ||
| Q1 24 | — | $-4.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $48.7M |
| Total Assets | $82.3M | $271.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | — | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $17.9M | — | ||
| Q1 25 | $19.5M | — | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $48.2M | $48.7M | ||
| Q3 25 | $52.9M | $210.8M | ||
| Q2 25 | $49.9M | $90.1M | ||
| Q1 25 | $45.2M | $1.9M | ||
| Q4 24 | $43.2M | $3.8M | ||
| Q3 24 | $32.4M | $5.0M | ||
| Q2 24 | $28.6M | $6.5M | ||
| Q1 24 | — | $22.1M |
| Q4 25 | $82.3M | $271.1M | ||
| Q3 25 | $82.3M | $419.7M | ||
| Q2 25 | $78.5M | $123.8M | ||
| Q1 25 | $73.9M | $15.1M | ||
| Q4 24 | $73.4M | $17.5M | ||
| Q3 24 | $61.6M | $18.6M | ||
| Q2 24 | $91.5M | $23.5M | ||
| Q1 24 | — | $56.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-2.7M |
| Free Cash FlowOCF − Capex | $1.6M | $-2.7M |
| FCF MarginFCF / Revenue | 17.8% | -33.5% |
| Capex IntensityCapex / Revenue | 4.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-22.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-2.7M | ||
| Q3 25 | $-3.7M | $-9.8M | ||
| Q2 25 | $-5.2M | $-8.4M | ||
| Q1 25 | $-5.1M | $-778.7K | ||
| Q4 24 | $4.0M | $-1.4M | ||
| Q3 24 | $4.1M | $-2.0M | ||
| Q2 24 | $-3.6M | $-101.4K | ||
| Q1 24 | — | $783.5K |
| Q4 25 | $1.6M | $-2.7M | ||
| Q3 25 | $-4.2M | $-9.8M | ||
| Q2 25 | $-5.7M | $-8.8M | ||
| Q1 25 | $-5.4M | $-809.3K | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | $-2.1M | ||
| Q2 24 | $-3.8M | $-1.0M | ||
| Q1 24 | — | $600.9K |
| Q4 25 | 17.8% | -33.5% | ||
| Q3 25 | -23.7% | -106.0% | ||
| Q2 25 | -36.2% | -205.4% | ||
| Q1 25 | -53.0% | -25.6% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | -49.2% | ||
| Q2 24 | -28.1% | -20.5% | ||
| Q1 24 | — | 11.5% |
| Q4 25 | 4.4% | 0.2% | ||
| Q3 25 | 2.8% | 0.2% | ||
| Q2 25 | 2.8% | 9.0% | ||
| Q1 25 | 3.0% | 1.0% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 0.5% | 3.8% | ||
| Q2 24 | 1.3% | 18.5% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | -0.15× | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
UPXI
Segment breakdown not available.
